NASDAQ: CRONCronos Group Inc Stock
$1.89+0.03 (+1.61%)
Updated Mar 14, 2025
CRON Price
$1.89
Fair Value Price
N/A
Market Cap
$722.98M
52 Week Low
$1.83
52 Week High
$3.14
P/E
N/A
P/B
0.68x
P/S
6.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$117.62M
Earnings
$41.08M
Gross Margin
21.4%
Operating Margin
-12.22%
Profit Margin
34.9%
Debt to Equity
0.05
Operating Cash Flow
$19M
Beta
1.26
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CRON Overview
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRON's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
CRON
Ranked#45 of 59
Ranked#45 of 59
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.58 | A | |
| $21.25 | A | |
| $5.01 | A |
Be the first to know about important CRON news, forecast changes, insider trades & much more!
CRON News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRON is good value based on its book value relative to its share price (0.68x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.21x)
P/B vs Industry Valuation
CRON's Earnings (EBIT) of -$14.38M can safely cover interest payments on company debt ($1.03M)
Interest Coverage Financials
CRON's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
There are 30 more CRON due diligence checks available for Premium users.
Valuation
CRON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
9.61x
Market
3,446.61x
CRON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.68x
Industry
2.21x
CRON is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRON's financial health
Profit margin
Revenue
$30.3M
Net Income
$43.7M
Profit Margin
144.3%
CRON's Earnings (EBIT) of -$14.38M... subscribe to Premium to read more.
Interest Coverage Financials
CRON's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$55.3M
Debt to equity
0.05
CRON's short-term assets ($936.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRON's short-term assets ($936.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRON's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.7M
Investing
-$5.0M
Financing
-$313.0k
CRON's operating cash flow ($18.84M)... subscribe to Premium to read more.
Debt Coverage Financials
CRON vs Pharmaceutical Stocks
Cronos Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.